Literature DB >> 17505262

Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.

Olivier Preynat-Seauve1, Emmanuel Contassot, Prisca Schuler, Lars E French, Bertrand Huard.   

Abstract

Dendritic cells are the most potent antigen-presenting cells inducing innate and adaptive immune response. Dendritic cells infiltrate melanomas, but their ability to induce host antitumor immunity remains obscure. In a previous study, we have observed that melanoma-infiltrating dendritic cells have the capacity to process antigens and migrate to lymph nodes to prime T lymphocytes. Here, we observed that melanoma-infiltrating dendritic cells extracted from melanoma without any additional manipulations were able to protect naive mice against a lethal challenge with the tumor. Remarkably, this was achieved with reinjection of 10(5) melanoma-infiltrating dendritic cells, a number that did not exceed the total number of melanoma-infiltrating dendritic cells recovered from one single tumor. Three observations indicate that protection was due to the natural loading of melanoma-infiltrating dendritic cells with tumor antigens. First, the protective effect was not observed with equivalent numbers of bone marrow-derived dendritic cells. Second, the protection induced was specific for the tumor from which the tumor-infiltrating dendritic cells were isolated. Third, depletion experiments indicate that both CD4+ and CD8+ T lymphocytes were required during the effector phase of the antitumor response. Hence, designing strategies aimed at rendering melanoma-infiltrating dendritic cells visible to host T cells may boost spontaneous antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505262     DOI: 10.1097/CMR.0b013e3281844531

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Modeling cancer-immune responses to therapy.

Authors:  L G dePillis; A Eladdadi; A E Radunskaya
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-04       Impact factor: 2.745

2.  Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation.

Authors:  Alison M McDonnell; Andrew J Currie; Matthew Brown; Kasia Kania; Ben Wylie; Amanda Cleaver; Richard Lake; Bruce W S Robinson
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

Review 3.  Endoplasmic Reticulum Stress Pathway, the Unfolded Protein Response, Modulates Immune Function in the Tumor Microenvironment to Impact Tumor Progression and Therapeutic Response.

Authors:  Manuel U Ramirez; Salvador R Hernandez; David R Soto-Pantoja; Katherine L Cook
Journal:  Int J Mol Sci       Date:  2019-12-25       Impact factor: 5.923

4.  Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.

Authors:  Jared S Klarquist; Edith M Janssen
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

5.  A model of dendritic cell therapy for melanoma.

Authors:  Lisette Depillis; Angela Gallegos; Ami Radunskaya
Journal:  Front Oncol       Date:  2013-03-19       Impact factor: 6.244

Review 6.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

7.  The immunostimulatory effects of retinoblastoma cell supernatant on dendritic cells.

Authors:  Juan Ma; Huamin Han; Li Ma; Changzhen Liu; Xin Xue; Pan Ma; Xiaomei Li; Hua Tao
Journal:  Protein Cell       Date:  2014-03-04       Impact factor: 14.870

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.